Clinical trial
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in…
NCT02658214 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT02658214 |
|---|---|
| Title | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
| Official title | A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Pancreatic Ductal and 1 more |
| Intervention type | Biological, Drug |
| Interventions | paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5FU) |
| Enrollment | 32 |
| Start date | Apr 28, 2016 |
| Primary completion | Nov 14, 2019 |
| Completion | Nov 14, 2019 |
| First posted | Jan 18, 2016 |
| Last update posted | Aug 20, 2020 |
| Countries | Japan, South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: